Global Neoantigens Market, By Treatment (Combination Therapy and Mono Therapy), Therapeutic Specialty (Lung Cancer, Urinary System Cancer, Melanoma, Liver Cancer, Head and Neck Cancer, and Blood and Bone Marrow Cancer), Line of Therapy (First Line, Second Line, and Later Lines), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Neoantigens Market Analysis and Size
The rising prevalence of cancer has put a strain on healthcare systems globally. According to the World Health Organization (WHO), cancer was the major cause of death among people under the age of 70 years in 183 countries and the fourth top cause of mortality in 123 countries in 2019. The recent clinical developments in biotechnology and increasing investments in the research of neoantigens and associated mechanisms are expected to increase the global neoantigens market.
Data Bridge Market Research analyses a growth rate in the global neoantigens market in the forecast period 2023-2030. The expected CAGR of the global neoantigens market tends to be around 35.00% in the mentioned forecast period. The market was valued at USD 2.62 billion in 2022 and would grow to USD 29 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Neoantigens Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Combination Therapy and Mono Therapy), Therapeutic Specialty (Lung Cancer, Urinary System Cancer, Melanoma, Liver Cancer, Head and Neck Cancer, and Blood and Bone Marrow Cancer), Line of Therapy (First Line, Second Line, and Later Lines), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Achilles Therapeutics plc (U.K.), Advaxis Immunotherapies (U.S.), Genocea (U.S.), Gradalis, Inc.(U.S.), Gritstone bio (U.S.), Iovance Biotherapetics Inc (U.S.), Medigene AG (Germany), BioNTech SE (U.S.), Lilly (U.S.), Scicomvisuals (Netherlands), Moderna, Inc.(U.S.), F. Hoffmann-La Roche Ltd. (Switzerland)., Merck KGaA (Germany), Sun Pharmaceutical Industries Ltd. (India)
|
|
Market Opportunities
|
|
Market Definition
Neoantigens are known as newly formed antigens that are not previously recognized by the immune system. Neoantigens are used for targeted therapies for the treatment of cancerous cells. It is also tumor-specific and highly immunogenic. Therefore, neoantigens are not expressed in healthy tissue. The neoantigens play a major role in tumor-specific T-cell mediated antitumor response and cancer immunotherapies. Furthermore, many research studies stated that neoantigens could help in immune escape, immunoediting, and sensitivity to immune checkpoint inhibitors.
Global Neoantigens Market Dynamics
Drivers
- Increasing prevalence of cancers
The rising prevalence of different forms of cancer is estimated to enhance the market's growth. In 2012, WHO projected that 8.2 million people died globally due to various malignancies. Lung, colorectal, breast, and liver cancers were among the most common cancers, with lung, colorectal, and breast cancers being the most common. Brain tumors (medulloblastoma and glioma) and neuroblastoma are the most frequent solid tumors, whereas rhabdomyosarcoma and osteosarcoma are less common solid cancers.
- Higher demand for biotechnological advancements
Biotechnology advancements have resulted in a acceptance of immunotherapy, which is pushing its application in personalized medications. Immunotherapy is commonly used to treat cancer; a few treatments include neoantigens found on the surface of cancer cells. As a result, neoantigen use for cancer treatment is being far researched.
Opportunities
- Increasing government initiatives for cancer treatment
Numerous governments have launched initiatives and programs to improve cancer treatment and prevention. For instance, in 2017, the World Health Assembly passed Resolution Cancer (WHA70.12), an integrated approach to cancer prevention and control. The program has urged the WHO and other governments to increase the efforts to meet the targets outlined in the Global Action Plan (2013-2020) for the prevention and management of non-communicable diseases (NCDs) and the 2030 UN Agenda for Sustainable Development to reduce cancer-related premature deaths.
- Higher drug launches for fast patient recovery
There are varied drugs that are launched widely to increase the recovery process. For instance, in October 2019, Corning Incorporated launched two new products, Elplasia and Matrigel, to its organoid culture portfolio to provide new solutions to support spheroid and organoid culture models. Elplasia, a 3D cell culture microplate, features a microcavity technology that enables high-volume spheroid formation, culture, and analysis. The Matrigel matrix for organoid culture is optimized to support organoid growth and differentiation. Thus, this factor create many opportunities for market growth.
Restraints/Challenges
- High cost of neoantigens
The huge expenditure of the varied neoantigens hampers the market growth. It becomes quite unaffordable for many of the sections and thus restricts the market growth.
This global neoantigens market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global neoantigens market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Neoantigens Market Scope
The global neoantigens market is segmented on the basis of treatment, therapeutic specialty, line of therapy, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Therapeutic Specialty
- Lung Cancer
- Urinary System Cancer
- Melanoma
- Liver Cancer
- Head and Neck Cancer
- Blood and Bone Marrow Cancer
Treatment
- Combination Therapy
- Mono Therapy
Line of Therapy
- First Line
- Second Line
- Later Lines
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Neoantigens Market Regional Analysis/Insights
The global neoantigens market is analyzed and market size insights and trends are provided by treatment, therapeutic specialty, line of therapy, distribution channel and end-user as referenced above.
The major countries covered in the global neoantigens market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific is expected to have the highest market growth due to the presence of key product manufacturers, increasing research and development activities, and healthcare expenditure.
North America dominates the market due to the latest technology development and the presence of a variety of innovative drug molecules to enhance the treatment procedure.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Neoantigens Market Share Analysis
The global neoantigens market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global neoantigens market.
Key players operating in the global neoantigens market include:
- Achilles Therapeutics plc (U.K.)
- Advaxis Immunotherapies (U.S.)
- Genocea (U.S.)
- Gradalis, Inc.(U.S.)
- Gritstone bio (U.S.)
- Iovance Biotherapetics Inc (U.S.)
- Medigene AG (Germany)
- BioNTech SE (U.S.)
- Lilly (U.S.)
- Scicomvisuals (Netherlands)
- Moderna, Inc.(U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland).
- Merck KGaA (Germany)
- Sun Pharmaceutical Industries Ltd. (India)
SKU-